Selected research
Market Structure
Global Neuroprotective Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Neuroprotective Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Neuroprotective Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Neuroprotective Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Neuroprotective Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Neuroprotective Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Neuroprotective Drugs include Teva Pharmaceutical Industries Ltd, Novartis, Merck KGaA, Biogen, AstraZeneca, NeuroVive Pharmaceutical, Neuren Pharmaceuticals, Genervon Biopharmaceuticals and Ceregene, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Neuroprotective Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Neuroprotective Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Neuroprotective Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Neuroprotective Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.
Neuroprotective Drugs Segment by Company
Teva Pharmaceutical Industries Ltd
Novartis
Merck KGaA
Biogen
AstraZeneca
NeuroVive Pharmaceutical
Neuren Pharmaceuticals
Genervon Biopharmaceuticals
Ceregene
Bionure
BHR Pharma
Allon therapeutics
Neuroprotective Drugs Segment by Type
Cholinesterase inhibitors
Anti-inflammatory
Others
Neuroprotective Drugs Segment by Application
Alzheimer's disease
Parkinson's disease
Others
Neuroprotective Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuroprotective Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Neuroprotective Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuroprotective Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Neuroprotective Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neuroprotective Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Neuroprotective Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Neuroprotective Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Cholinesterase inhibitors
- Anti-inflammatory
- Others
Applications
- Alzheimer's disease
- Parkinson's disease
- Others
Companies covered
- Teva Pharmaceutical Industries Ltd
- Novartis
- Merck KGaA
- Biogen
- AstraZeneca
- NeuroVive Pharmaceutical
- Neuren Pharmaceuticals
- Genervon Biopharmaceuticals
- Ceregene
- Bionure
- BHR Pharma
- Allon therapeutics
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Neuroprotective Drugs Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Neuroprotective Drugs Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Neuroprotective Drugs Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Neuroprotective Drugs Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Neuroprotective Drugs Market Dynamics
- 2.1 Neuroprotective Drugs Industry Trends
- 2.2 Neuroprotective Drugs Industry Drivers
- 2.3 Neuroprotective Drugs Industry Opportunities and Challenges
- 2.4 Neuroprotective Drugs Industry Restraints
3 Neuroprotective Drugs Market by Manufacturers
- 3.1 Global Neuroprotective Drugs Revenue by Manufacturers (2021-2026)
- 3.2 Global Neuroprotective Drugs Sales by Manufacturers (2021-2026)
- 3.3 Global Neuroprotective Drugs Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Neuroprotective Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Neuroprotective Drugs Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Neuroprotective Drugs Manufacturers, Product Type & Application
- 3.7 Global Neuroprotective Drugs Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Neuroprotective Drugs Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Neuroprotective Drugs Players Market Share by Revenue in 2025
- 3.8.3 2025 Neuroprotective Drugs Tier 1, Tier 2, and Tier 3
4 Neuroprotective Drugs Market by Type
- 4.1 Neuroprotective Drugs Type Introduction
- 4.1.1 Cholinesterase inhibitors
- 4.1.2 Anti-inflammatory
- 4.1.3 Others
- 4.2 Global Neuroprotective Drugs Sales by Type
- 4.2.1 Global Neuroprotective Drugs Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Neuroprotective Drugs Sales by Type (2021-2032)
- 4.2.3 Global Neuroprotective Drugs Sales Market Share by Type (2021-2032)
- 4.3 Global Neuroprotective Drugs Revenue by Type
- 4.3.1 Global Neuroprotective Drugs Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Neuroprotective Drugs Revenue by Type (2021-2032)
- 4.3.3 Global Neuroprotective Drugs Revenue Market Share by Type (2021-2032)
5 Neuroprotective Drugs Market by Application
- 5.1 Neuroprotective Drugs Application Introduction
- 5.1.1 Alzheimer's disease
- 5.1.2 Parkinson's disease
- 5.1.3 Others
- 5.2 Global Neuroprotective Drugs Sales by Application
- 5.2.1 Global Neuroprotective Drugs Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Neuroprotective Drugs Sales by Application (2021-2032)
- 5.2.3 Global Neuroprotective Drugs Sales Market Share by Application (2021-2032)
- 5.3 Global Neuroprotective Drugs Revenue by Application
- 5.3.1 Global Neuroprotective Drugs Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Neuroprotective Drugs Revenue by Application (2021-2032)
- 5.3.3 Global Neuroprotective Drugs Revenue Market Share by Application (2021-2032)
6 Global Neuroprotective Drugs Sales by Region
- 6.1 Global Neuroprotective Drugs Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Neuroprotective Drugs Sales by Region (2021-2032)
- 6.2.1 Global Neuroprotective Drugs Sales by Region (2021-2026)
- 6.2.2 Global Neuroprotective Drugs Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Neuroprotective Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Neuroprotective Drugs Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Neuroprotective Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Neuroprotective Drugs Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Neuroprotective Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Neuroprotective Drugs Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Neuroprotective Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Neuroprotective Drugs Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Neuroprotective Drugs Revenue by Region
- 7.1 Global Neuroprotective Drugs Revenue by Region
- 7.1.1 Global Neuroprotective Drugs Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Neuroprotective Drugs Revenue by Region (2021-2026)
- 7.1.3 Global Neuroprotective Drugs Revenue by Region (2027-2032)
- 7.1.4 Global Neuroprotective Drugs Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Neuroprotective Drugs Revenue (2021-2032)
- 7.2.2 North America Neuroprotective Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Neuroprotective Drugs Revenue (2021-2032)
- 7.3.2 Europe Neuroprotective Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Neuroprotective Drugs Revenue (2021-2032)
- 7.4.2 Asia-Pacific Neuroprotective Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Neuroprotective Drugs Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Neuroprotective Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Teva Pharmaceutical Industries Ltd
- 8.1.1 Teva Pharmaceutical Industries Ltd Company Information
- 8.1.2 Teva Pharmaceutical Industries Ltd Business Overview
- 8.1.3 Teva Pharmaceutical Industries Ltd Neuroprotective Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Teva Pharmaceutical Industries Ltd Neuroprotective Drugs Product Portfolio
- 8.1.5 Teva Pharmaceutical Industries Ltd Recent Developments
- 8.2 Novartis
- 8.2.1 Novartis Company Information
- 8.2.2 Novartis Business Overview
- 8.2.3 Novartis Neuroprotective Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Novartis Neuroprotective Drugs Product Portfolio
- 8.2.5 Novartis Recent Developments
- 8.3 Merck KGaA
- 8.3.1 Merck KGaA Company Information
- 8.3.2 Merck KGaA Business Overview
- 8.3.3 Merck KGaA Neuroprotective Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Merck KGaA Neuroprotective Drugs Product Portfolio
- 8.3.5 Merck KGaA Recent Developments
- 8.4 Biogen
- 8.4.1 Biogen Company Information
- 8.4.2 Biogen Business Overview
- 8.4.3 Biogen Neuroprotective Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Biogen Neuroprotective Drugs Product Portfolio
- 8.4.5 Biogen Recent Developments
- 8.5 AstraZeneca
- 8.5.1 AstraZeneca Company Information
- 8.5.2 AstraZeneca Business Overview
- 8.5.3 AstraZeneca Neuroprotective Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 AstraZeneca Neuroprotective Drugs Product Portfolio
- 8.5.5 AstraZeneca Recent Developments
- 8.6 NeuroVive Pharmaceutical
- 8.6.1 NeuroVive Pharmaceutical Company Information
- 8.6.2 NeuroVive Pharmaceutical Business Overview
- 8.6.3 NeuroVive Pharmaceutical Neuroprotective Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 NeuroVive Pharmaceutical Neuroprotective Drugs Product Portfolio
- 8.6.5 NeuroVive Pharmaceutical Recent Developments
- 8.7 Neuren Pharmaceuticals
- 8.7.1 Neuren Pharmaceuticals Company Information
- 8.7.2 Neuren Pharmaceuticals Business Overview
- 8.7.3 Neuren Pharmaceuticals Neuroprotective Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Neuren Pharmaceuticals Neuroprotective Drugs Product Portfolio
- 8.7.5 Neuren Pharmaceuticals Recent Developments
- 8.8 Genervon Biopharmaceuticals
- 8.8.1 Genervon Biopharmaceuticals Company Information
- 8.8.2 Genervon Biopharmaceuticals Business Overview
- 8.8.3 Genervon Biopharmaceuticals Neuroprotective Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Genervon Biopharmaceuticals Neuroprotective Drugs Product Portfolio
- 8.8.5 Genervon Biopharmaceuticals Recent Developments
- 8.9 Ceregene
- 8.9.1 Ceregene Company Information
- 8.9.2 Ceregene Business Overview
- 8.9.3 Ceregene Neuroprotective Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Ceregene Neuroprotective Drugs Product Portfolio
- 8.9.5 Ceregene Recent Developments
- 8.10 Bionure
- 8.10.1 Bionure Company Information
- 8.10.2 Bionure Business Overview
- 8.10.3 Bionure Neuroprotective Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Bionure Neuroprotective Drugs Product Portfolio
- 8.10.5 Bionure Recent Developments
- 8.11 BHR Pharma
- 8.11.1 BHR Pharma Company Information
- 8.11.2 BHR Pharma Business Overview
- 8.11.3 BHR Pharma Neuroprotective Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.11.4 BHR Pharma Neuroprotective Drugs Product Portfolio
- 8.11.5 BHR Pharma Recent Developments
- 8.12 Allon therapeutics
- 8.12.1 Allon therapeutics Company Information
- 8.12.2 Allon therapeutics Business Overview
- 8.12.3 Allon therapeutics Neuroprotective Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.12.4 Allon therapeutics Neuroprotective Drugs Product Portfolio
- 8.12.5 Allon therapeutics Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Neuroprotective Drugs Value Chain Analysis
- 9.1.1 Neuroprotective Drugs Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Neuroprotective Drugs Production Mode & Process
- 9.2 Neuroprotective Drugs Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Neuroprotective Drugs Distributors
- 9.2.3 Neuroprotective Drugs Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst